Language Switcher for Asiarecords

CryoCord Recognised by ASIA Records for First and Most Mesenchymal Stem Cells Cultured by a Private Stem Cell Bank Laboratory

ASIA Records is proud to officially recognise CryoCord for achieving:

First and Most Mesenchymal Stem Cells Cultured by a Private Stem Cell Bank Laboratory
(Storage service first launched 2009; MSC culturing commenced November 2008; 1.71 trillion MSCs cumulatively cultured as of November 2025)

This recognition highlights CryoCord’s achievement in cumulatively culturing 1.71 trillion mesenchymal stem cells (MSCs) as of November 2025, representing a significant milestone in specialised cell cultivation and laboratory biotechnology.

Achieving 1.71 Trillion Mesenchymal Stem Cells Cultured

CryoCord’s recognised achievement is based on its cumulative laboratory records documenting the cultivation of 1,713,032.8 million mesenchymal stem cells, equivalent to approximately 1.71 trillion cells, as of November 2025.

The recorded total includes approximately 949,122.4 million allogeneic and customised CordMSCs, 763,012.3 million Infant CordMSCs and 898.1 million ToothMSCs.

These figures demonstrate the scale of CryoCord’s cell cultivation activities across different categories, reflecting the development of its specialised laboratory capabilities over an extended period.

Building More Than 17 Years of Stem Cell Cultivation Experience

CryoCord commenced its mesenchymal stem cell cultivation activities in November 2008, before launching its MSC storage services in 2009.

Through continued scientific and technical development, the company expanded its capabilities in cell processing, culture expansion, cryopreservation and specialised laboratory operations.

The achievement reflects CryoCord’s progression from conventional stem cell banking towards a wider biotechnology organisation with capabilities across multiple cell-based technologies.

Strengthening Laboratory Standards and Cell Technology Innovation

Cryocord’s laboratory operations are supported by specialised cell-processing facilities, cleanroom infrastructure and quality management procedures, with reported AABB accreditation and cGMP-certified facilities relevant to its activities.

The group has expanded into natural killer cells, induced pluripotent stem cells, CAR T-cell technologies and regenerative medicine research, and reports 15 granted patents, comprising three United States patents and 12 Malaysian patents, alongside contributions to more than 300 peer-reviewed scientific publications.

The ASIA Records recognition acknowledges CryoCord’s cumulative MSC cultivation milestone and its sustained investment in laboratory infrastructure, scientific expertise and cell-based research, highlighting Malaysia’s contribution to biotechnology development across Asia.

A Milestone Moment of Recognition

ASIA Records recognition was officially presented on 20 October 2026 at Hyatt Regency Kuala Lumpur at KL Midtown, during the 10th Gather of Achievers – ASEAN Records & ASIA Records Gala Night 2026.

The recognition was received on stage by James Then Khong Lek, Managing Director of CryoCord Group, representing CryoCord and its scientific, laboratory and operational teams whose contributions supported the cultivation of 1.71 trillion mesenchymal stem cells.

Voices of Leadership

Reflecting on the recognition and CryoCord’s journey, James Then Khong Lek, Managing Director of CryoCord Group, shared:

“Receiving ASIA Records recognition is a proud achievement for CryoCord and everyone who has contributed to our scientific and technological development.

Culturing 1.71 trillion mesenchymal stem cells is the result of many years of sustained laboratory work, technical expertise and investment in specialised infrastructure. We believe that continued progress in biotechnology depends on strong scientific foundations, responsible research and collaboration across the industry.

This recognition motivates us to continue strengthening our capabilities in cell and gene technologies while supporting the development of Malaysia’s biotechnology sector and its participation in the wider Asian scientific community.”

About CryoCord

CryoCord Group is a Malaysian biotechnology organisation established in 2002, specialising in stem cell banking, cell processing, immune cell technologies and cell and gene research.

Headquartered at the Bio-X Centre in Cyberjaya, Malaysia, the organisation has developed its operations from cord blood storage into a wider range of specialised biological services and research activities.

Its capabilities include mesenchymal stem cells, induced pluripotent stem cells, natural killer cells, CAR T-cell technologies, cryopreservation and regenerative medicine research, supported by specialised laboratory facilities and scientific expertise.

Through its continued commitment to laboratory development, scientific collaboration and responsible research, CryoCord aims to contribute to advances in biotechnology and cell-based technology across Malaysia and Asia.

For more information, visit:
https://cryocord.com.my/